Apricus Biosciences Inc (APRI) 2.38 $APRI
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Apricus Biosciences' partner to be the first to launch Vitaros for treating erectile dysfunction in Europe
M2 - Thu Apr 17, 5:23AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Wednesday the first shipment of its novel topical on-demand treatment for erectile dysfunction (ED) Vitaros in the UK.
Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros(R)
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Takeda UK to be the First to Launch Vitaros in Europe
Apricus Biosciences and Its European Partners to Sponsor Symposium on Vitaros(R) at the European Association of Urology (EAU) Congress, Stockholm
GlobeNewswire - Mon Apr 07, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company, along with its European commercial partners, is sponsoring a symposium - "A New Paradigm in the Treatment of ED - The Topical Option" - during the European Association of Urology (EAU) Congress. Vitaros is Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"
, approved in Canada and nine countries in Europe. The symposium will take place in the Stockholmsmassan Exhibition & Convention Center, Room K2, on Friday, April 11 at 4:15 pm DST.
Apricus Biosciences receives national phase approval for Vitaros in Luxembourg & on track for its planned market launch in 2014
M2 - Fri Apr 04, 7:31AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) reported on Thursday the receipt of national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED), Vitaros, in Europe from the Ministry of Health of Luxembourg.
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Luxembourg
GlobeNewswire - Thu Apr 03, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction ("ED" .
Apricus' Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:54PM CDT
Apricus posted a loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents per share and far better than the year-ago loss of 25 cents per share.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Apricus Biosciences Provides Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Mon Mar 17, 3:03PM CDT
- Vitaros Remains on Track to Launch in Europe and Canada in 2014 -
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
Apricus Shares Marginally Down on Vitaros Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 2:44PM CST
Apricus signs deal with Recordati for the commercialization of Vitaros in some countries in Europe and Africa
RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES
GlobeNewswire - Mon Feb 10, 6:06AM CST
Recordati announces the signature of an exclusive license agreement with Apricus Biosciences Inc., (Nasdaq: APRI), a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros(R) (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.
Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream - Vitaros(R) in Spain, Russia, Turkey and Other Global Territories
Thomson Reuters ONE - Mon Feb 10, 6:02AM CST
Apricus Eligible to Receive Up to Approximately $50 Million in Upfront and Milestone Payments, Plus Double-Digit Tiered Royalties
Raynauds Disease - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x6c6p9/raynauds_disease) has announced the addition of the "Raynauds Disease - Pipeline Review, H2 2013" report to their offering. 'Raynauds Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Raynauds Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Raynauds Disease. Scope - A snapshot of the global therapeutic scenario for Raynauds Disease. - A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Raynauds Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Raynauds Disease Overview Therapeutics Development Pipeline Products for Raynauds Disease - Overview Pipeline Products for Raynauds Disease - Comparative Analysis Raynauds Disease - Therapeutics under Development by Companies Raynauds Disease - Therapeutics under Investigation by Universities/Institutes Raynauds Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Raynauds Disease - Products under Development by Companies Raynauds Disease - Products under Investigation by Universities/Institutes Raynauds Disease - Companies Involved in Therapeutics Development Raynauds Disease - Therapeutics Assessment Drug Profiles nitroglycerin - Drug Profile fasudil - Drug Profile udenafil - Drug Profile riociguat - Drug Profile alprostadil - Drug Profile MDT-012 - Drug Profile ELS-140 - Drug Profile Yohimbine Dimers - Drug Profile Yohimbine Monomers - Drug Profile Raynauds Disease - Recent Pipeline Updates Raynauds Disease - Dormant Projects Raynauds Disease - Discontinued Products Raynauds Disease - Product Development Milestones Featured News & Press Releases Companies Mentioned Bayer AG Apricus Biosciences, Inc. MediQuest Therapeutics, Inc. MicroDose Therapeutx, Inc. Exodos Life Science Limited Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/x6...ds_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Apricus Biosciences' partner to be the first to launch Vitaros for treating erectile dysfunction in Europe
M2 - Thu Apr 17, 5:23AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Wednesday the first shipment of its novel topical on-demand treatment for erectile dysfunction (ED) Vitaros in the UK.
Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros(R)
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Takeda UK to be the First to Launch Vitaros in Europe
Apricus Biosciences and Its European Partners to Sponsor Symposium on Vitaros(R) at the European Association of Urology (EAU) Congress, Stockholm
GlobeNewswire - Mon Apr 07, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company, along with its European commercial partners, is sponsoring a symposium - "A New Paradigm in the Treatment of ED - The Topical Option" - during the European Association of Urology (EAU) Congress. Vitaros is Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"
, approved in Canada and nine countries in Europe. The symposium will take place in the Stockholmsmassan Exhibition & Convention Center, Room K2, on Friday, April 11 at 4:15 pm DST. Apricus Biosciences receives national phase approval for Vitaros in Luxembourg & on track for its planned market launch in 2014
M2 - Fri Apr 04, 7:31AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) reported on Thursday the receipt of national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED), Vitaros, in Europe from the Ministry of Health of Luxembourg.
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Luxembourg
GlobeNewswire - Thu Apr 03, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"
. Apricus' Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:54PM CDT
Apricus posted a loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents per share and far better than the year-ago loss of 25 cents per share.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Apricus Biosciences Provides Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Mon Mar 17, 3:03PM CDT
- Vitaros Remains on Track to Launch in Europe and Canada in 2014 -
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
Apricus Shares Marginally Down on Vitaros Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 2:44PM CST
Apricus signs deal with Recordati for the commercialization of Vitaros in some countries in Europe and Africa
RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES
GlobeNewswire - Mon Feb 10, 6:06AM CST
Recordati announces the signature of an exclusive license agreement with Apricus Biosciences Inc., (Nasdaq: APRI), a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros(R) (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.
Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream - Vitaros(R) in Spain, Russia, Turkey and Other Global Territories
Thomson Reuters ONE - Mon Feb 10, 6:02AM CST
Apricus Eligible to Receive Up to Approximately $50 Million in Upfront and Milestone Payments, Plus Double-Digit Tiered Royalties
Raynauds Disease - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/x6c6p9/raynauds_disease) has announced the addition of the "Raynauds Disease - Pipeline Review, H2 2013" report to their offering. 'Raynauds Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Raynauds Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Raynauds Disease. Scope - A snapshot of the global therapeutic scenario for Raynauds Disease. - A review of the Raynauds Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Raynauds Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Raynauds Disease Overview Therapeutics Development Pipeline Products for Raynauds Disease - Overview Pipeline Products for Raynauds Disease - Comparative Analysis Raynauds Disease - Therapeutics under Development by Companies Raynauds Disease - Therapeutics under Investigation by Universities/Institutes Raynauds Disease - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Raynauds Disease - Products under Development by Companies Raynauds Disease - Products under Investigation by Universities/Institutes Raynauds Disease - Companies Involved in Therapeutics Development Raynauds Disease - Therapeutics Assessment Drug Profiles nitroglycerin - Drug Profile fasudil - Drug Profile udenafil - Drug Profile riociguat - Drug Profile alprostadil - Drug Profile MDT-012 - Drug Profile ELS-140 - Drug Profile Yohimbine Dimers - Drug Profile Yohimbine Monomers - Drug Profile Raynauds Disease - Recent Pipeline Updates Raynauds Disease - Dormant Projects Raynauds Disease - Discontinued Products Raynauds Disease - Product Development Milestones Featured News & Press Releases Companies Mentioned Bayer AG Apricus Biosciences, Inc. MediQuest Therapeutics, Inc. MicroDose Therapeutx, Inc. Exodos Life Science Limited Dong-A Socio Holdings Co Ltd For more information visit http://www.researchandmarkets.com/research/x6...ds_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
